Pigment Cell Tumors of the Skin in Dogs (Melanocytic Tumors)

  • Occurrence: rarer
  • Location of disease: General/Whole body
Author: Dr. med. vet. Gisa Löwe | Last modified: 10.08.2026
Open table of contents

When to visit the vet?

Non-urgent see a veterinarian within 2–3 days

?

If the condition worsens / symptoms persist, consult a veterinarian.

Download/Print

Definition

Melanocytic tumors in dogs are neoplasms that originate from pigment cells, also known as melanocytes. These Tumors can be either benign or malignant and often occur in the skin, mouth, or on the toes.

The most important facts at a glance

Melanocytic tumors in dogs arise from uncontrolled growth of melanocytes, which are pigment cells that produce melanin. This tumor formation can be triggered by genetic mutations and possibly by environmental factors such as UV radiation. Some dog breeds such as Scottish Terriers, Golden Retrievers, and Poodles are more susceptible to these tumors. Symptoms often include dark Skin changes or masses that slowly grow larger, as well as occasional ulcers in the oral area or on the toes.

Diagnosis is made through a thorough examination and a biopsy to determine whether the tumor is benign or malignant. Imaging procedures help assess the spread of the tumor. Treatment depends on the tumor type and often includes surgical removal. For malignant melanomas, a combination of surgery, radiation therapy, chemotherapy, and immunotherapy may be used. Regular follow-up examinations are important to detect a recurrence. The prognosis depends on the type and progression of the tumor; benign tumors often have a better outlook than malignant ones, especially when metastases are present.

Although there are no specific prevention measures, regular veterinary check-ups, limiting sun exposure, and a healthy lifestyle can reduce the risk. Genetic counseling for breeding animals could help minimize predisposing genetic factors.

Causes

Melanocytes are specialized cells that produce the pigment melanin, which is responsible for the coloring of skin, hair, and eyes. These cells are located in the basal layer of the epidermis and play a central role in protecting the skin from UV radiation. In dogs, melanocytes are also found in mucous membranes and at the base of the nail beds.

Tumor formation in melanocytes can be triggered by genetic mutations that promote uncontrolled cell growth and division. These mutations can occur spontaneously or be favored by environmental factors such as UV radiation. In dogs, however, the exact pathophysiological mechanisms are often complex and not fully understood.

Some genetic predispositions and breed susceptibilities have been observed in dogs. Certain breeds such as Scottish Terriers, Golden Retrievers, and Poodles appear to have a higher risk of developing melanocytic tumors. This could be due to genetic factors that are more common in these breeds.

Symptoms

Rare symptoms:

The symptoms of melanocytic tumors in dogs can vary depending on the location and type of the tumor. Skin tumors often appear as dark, raised masses that can vary in size and shape. These Tumors can ulcerate or bleed, especially if irritated.

With tumors in the oral cavity, dogs may have difficulty eating, excessive salivation, or bad breath. These tumors are often more aggressive and tend to grow faster and invade surrounding tissue.

Melanocytic tumors on the toes can cause Swelling and Lameness. These Tumors are often difficult to detect until they have reached a considerable size and cause Pain.

Therapy

The treatment of melanocytic tumors depends on the location, size, and degree of malignancy. Surgical removal is the preferred method for benign tumors and for locally confined malignant tumors.

For malignant melanomas that cannot be completely removed or have already metastasized, a combination therapy of surgery, radiation therapy, and chemotherapy may be considered. A newer option is immunotherapy, which supports the dog’s immune system to better recognize and fight tumor cells.

Postoperative care and regular follow-up examinations are crucial to detect and treat a recurrence of the tumor early. The dog’s quality of life should always be a priority when choosing treatment methods.

Prognosis and follow-up care

The prognosis for dogs with melanocytic tumors varies significantly depending on the tumor type and treatment progress. Benign melanomas that can be completely surgically removed generally have a good prognosis.

Malignant melanomas, especially those in the oral cavity or with metastases, have a poorer prognosis. However, life expectancy can be extended through early and aggressive treatment. Regular follow-up examinations are important to detect a recurrence of the tumor early.

Prevention

There is currently no specific prevention for melanocytic tumors in dogs. However, certain measures can help reduce the risk. These include regular veterinary examinations to detect Skin changes early, as well as limiting sun exposure in dogs with light or thin coats.

A healthy lifestyle, including a balanced diet and adequate exercise, can promote the dog’s overall well-being and possibly reduce the risk of developing tumors. Genetic counseling when selecting breeding animals can help reduce the spread of genetic predispositions for melanocytic tumors in certain breeds.

Outlook on current research

*]:pointer-events-auto scroll-mt-[calc(var(–header-height)+min(200px,max(70px,20svh)))]” dir=”auto” data-turn-id=”request-WEB:df9ab6c9-c443-4638-a165-d9b345096fef-16″ data-testid=”conversation-turn-34″ data-scroll-anchor=”true” data-turn=”assistant”>

Melanocytic tumors are neoplasms of pigment cells. These include benign forms such as melanocytoma as well as malignant ones such as melanoma. In veterinary medicine, it is particularly important that these tumors behave very differently biologically depending on location: skin tumors are often less aggressive, while oral, digital, or ocular melanomas can be significantly more problematic. This is precisely why research is increasingly shifting from mere diagnosis to the question of which tumor actually metastasizes and which does not. (merckvetmanual.com, pubmed.ncbi.nlm.nih.gov)

A central research field is more precise prognostic classification. In addition to classical histopathology, mitotic count, Ki-67, immunohistochemistry, and molecular markers are being studied to better predict biological behavior. The goal is to distinguish benign from aggressive tumors earlier and more reliably, and thus plan surgery, follow-up care, and systemic therapy more precisely. (pubmed.ncbi.nlm.nih.gov)

A second focus is immunotherapy. Especially with malignant melanoma, research is trying to better activate the body’s own immune system against tumor cells. At the same time, work is being done on combinations of surgery, radiation therapy, and systemic treatment. (frontiersin.org)

Overall, the outlook is good: research is clearly moving toward personalized tumor medicine, away from blanket statements toward more precise risk assessment and more individualized treatment concepts.

Frequently Asked Questions (FAQs)

1. What are melanocytic tumors?
Melanocytic tumors arise from melanocytes, the cells that produce the skin pigment melanin. In dogs, they occur on the skin, in the mouth, on the toes, and in the eye. They range from benign melanocytomas to highly aggressive malignant melanomas.
2. How does a benign melanocytoma differ from a malignant melanoma?
Both consist of pigmented cells but differ in growth, cellular characteristics, and metastatic behavior. Melanocytomas grow slowly, have little cellular atypia, and do not metastasize. Malignant melanomas grow faster, show high mitotic rates, pronounced cellular atypia, and tend to metastasize to lymph nodes and lungs.
3. At which body sites do melanocytic tumors occur?
Most commonly on the skin (often benign), in the oral cavity (usually malignant), on the toes and nail fold (variable), and in the eye. Location has a major influence on biological behavior. Oral and digital melanomas are generally considered highly malignant.
4. Which dogs are particularly affected?
Older dogs, often darkly pigmented breeds such as Schnauzers, Scottish Terriers, Cocker Spaniels, Chow Chows, and Golden Retrievers. Black skin and heavily pigmented mucous membranes are risk factors but do not explain all cases.
5. How is the diagnosis made?
Fine-needle aspiration is a good first step but does not replace histopathological examination. The definitive classification (benign vs. malignant, subtype, mitotic rate, Ki-67 index) is made on the biopsy specimen. If a melanoma is suspected, lymph nodes and thorax are additionally examined for metastases.
6. How is therapy planned?
Surgery with adequate safety margins is always the foundation. For malignant tumors, depending on location and stage, radiation therapy, chemotherapy (carboplatin), and immunotherapy with a DNA vaccine are added. Treatment is individualized based on location, size, and findings.
7. What is the prognosis for malignant melanomas?
Oral melanomas without metastases have a median survival time of about eight to twelve months after surgery, longer with multimodal therapy. Digital melanomas respond somewhat better to surgery and chemotherapy. Cutaneous melanomas in hairless areas are often highly malignant.
8. Do benign melanocytomas metastasize?
No, true melanocytomas do not metastasize by definition. However, they are occasionally misclassified as malignant or vice versa. A histopathological assessment by an experienced pathologist is therefore important.
9. How common are relapses?
For benign tumors with adequate safety margins, relapses are rare. For malignant forms, the relapse rate depends on the completeness of resection. After incomplete removal or at difficult-to-operate sites, the relapse rate is high, which is why adjuvant radiation therapy is advisable.
10. Can multiple melanocytic tumors occur simultaneously?
Yes, especially Schnauzers and some other predisposed breeds develop multiple cutaneous melanocytomas simultaneously. Each new nodule must be assessed individually, as a single malignant tumor can also occur among many benign changes.

Literature

  • Polton, G., Borrego, J. F., Clemente-Vicario, F., Clifford, C. A., Jagielski, D., Kessler, M., Kobayashi, T., Lanore, D., Queiroga, F. L., Rowe, A. T., Vajdovich, P., & Bergman, P. J. (2024). Melanoma of the dog and cat: Consensus and guidelines. Frontiers in Veterinary Science, 11, Article 1359426. https://doi.org/10.3389/fvets.2024.1359426
  • Smedley, R. C., Bongiovanni, L., Bacmeister, C., Clifford, C. A., Christensen, N., Dreyfus, J. M., Gary, J. M., Pavuk, A., Rowland, P. H., Swanson, C., Tripp, C., Woods, J. P., & Bergman, P. J. (2022). Diagnosis and histopathologic prognostication of canine melanocytic neoplasms: A consensus of the Oncology-Pathology Working Group. Veterinary and Comparative Oncology, 20(4), 739–751. https://doi.org/10.1111/vco.12827
  • Smedley, R. C., Sebastian, K., & Kiupel, M. (2022). Diagnosis and prognosis of canine melanocytic neoplasms. Veterinary Sciences, 9(4), Article 175. https://doi.org/10.3390/vetsci9040175
  • Smedley, R. C., Spangler, W. L., Esplin, D. G., Kitchell, B. E., Bergman, P. J., Ho, H.-Y., Bergin, I. L., & Kiupel, M. (2011). Prognostic markers for canine melanocytic neoplasms: A comparative review of the literature and goals for future investigation. Veterinary Pathology, 48(1), 54–72. https://doi.org/10.1177/0300985810390717
  • Spangler, W. L., & Kass, P. H. (2006). The histologic and epidemiologic bases for prognostic considerations in canine melanocytic neoplasia. Veterinary Pathology, 43(2), 136–149. https://doi.org/10.1354/vp.43-2-136
  • Laver, T., Feldhaeusser, B. R., Robat, C. S., Baez, J. L., Cronin, K. L., Buracco, P., Annoni, M., Regan, R. C., McMillan, S. K., Curran, K. M., Selmic, L. E., Shiu, K. B., Clark, K., Fagan, E., & Thamm, D. H. (2018). Post-surgical outcome and prognostic factors in canine malignant melanomas of the haired skin: 87 cases (2003–2015). The Canadian Veterinary Journal, 59(9), 981–987.